Open AccessBreast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Author(s) -
Rowan T. Chlebowski,
Lewis H. Kuller,
Ross L. Prentice,
Marcia L. Stefanick,
JoAnn E. Manson,
Margery Gass,
Aaron K. Aragaki,
Judith K. Ockene,
Dorothy S. Lane,
Gloria E. Sarto,
Aleksandar Rajkovic,
Robert S. Schenken,
Susan L. Hendrix,
Peter M. Ravdin,
Thomas E. Rohan,
Shagufta Yasmeen,
Garnet L. Anderson
Publication year - 2009
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa0807684
Subject(s) - medicine , breast cancer , estrogen , progestin , postmenopausal women , hormone therapy , incidence (geometry) , gynecology , women's health initiative , menopause , cancer , hormone replacement therapy (female to male) , hormone , oncology , obstetrics , physiology , physics , optics , testosterone (patch)
Following the release of the 2002 report of the Women's Health Initiative (WHI) trial of estrogen plus progestin, the use of menopausal hormone therapy in the United States decreased substantially. Subsequently, the incidence of breast cancer also dropped, suggesting a cause-and-effect relation between hormone treatment and breast cancer. However, the cause of this decrease remains controversial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom